Trials / Completed
CompletedNCT01153841
Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam
Primary Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, in Healthy Infants in Vietnam When Co-administered With GSK Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 12 Weeks
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the safety and reactogenicity of Synflorix™ (GSK 1024850A) given as a 3-dose primary immunization course when co-administered with Infanrix hexa™ vaccine at 2, 3 and 4 months of age in infants in Vietnam.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Synflorix™( GSK1024850A) | Intramuscular, 3 doses |
| BIOLOGICAL | Infanrix hexa™ | Intramuscular, 3 doses |
Timeline
- Start date
- 2011-02-17
- Primary completion
- 2011-07-26
- Completion
- 2011-07-26
- First posted
- 2010-06-30
- Last updated
- 2020-01-02
- Results posted
- 2017-02-27
Locations
1 site across 1 country: Vietnam
Source: ClinicalTrials.gov record NCT01153841. Inclusion in this directory is not an endorsement.